Division of Endocrinology, Department of Medicine, University of Arizona College of Medicine, Tucson, Arizona; and.
Division of Neonatology, Department of Pediatrics, Columbia University, New York, New York.
Am J Respir Cell Mol Biol. 2020 Feb;62(2):231-242. doi: 10.1165/rcmb.2019-0065OC.
NFU1 is a mitochondrial protein that is involved in the biosynthesis of iron-sulfur clusters, and its genetic modification is associated with disorders of mitochondrial energy metabolism. Patients with autosomal-recessive inheritance of the NFU1 mutation G208C have reduced activity of the respiratory chain Complex II and decreased levels of lipoic-acid-dependent enzymes, and develop pulmonary arterial hypertension (PAH) in ∼70% of cases. We investigated whether rats with a human mutation in NFU1 are also predisposed to PAH development. A point mutation in rat NFU1 (human G208C) was introduced through CRISPR/Cas9 genome editing. Hemodynamic data, tissue samples, and fresh mitochondria were collected and analyzed. NFU1 rats showed increased right ventricular pressure, right ventricular hypertrophy, and high levels of pulmonary artery remodeling. Computed tomography and angiography of the pulmonary vasculature indicated severe angioobliterative changes in NFU1 rats. Importantly, the penetrance of the PAH phenotype was found to be more prevalent in females than in males, replicating the established sex difference among patients with PAH. Male and female homozygote rats exhibited decreased expression and activity of mitochondrial Complex II, and markedly decreased pyruvate dehydrogenase activity and lipoate binding. The limited development of PAH in males correlated with the preserved levels of oligomeric NFU1, increased expression of ISCU (an alternative branch of the iron-sulfur assembly system), and increased complex IV activity. Thus, the male sex has additional plasticity to overcome the iron-sulfur cluster deficiency. Our work describes a novel, humanized rat model of NFU1 deficiency that showed mitochondrial dysfunction similar to that observed in patients and developed PAH with the same sex dimorphism.
NFU1 是一种线粒体蛋白,参与铁硫簇的生物合成,其基因修饰与线粒体能量代谢障碍有关。常染色体隐性遗传 NFU1 突变 G208C 的患者呼吸链复合物 II 活性降低,脂酰基辅酶 A 依赖性酶水平降低,约 70%的患者发展为肺动脉高压 (PAH)。我们研究了 NFU1 中存在人类突变的大鼠是否也易患 PAH 发展。通过 CRISPR/Cas9 基因组编辑引入大鼠 NFU1(人类 G208C)点突变。收集和分析血流动力学数据、组织样本和新鲜线粒体。NFU1 大鼠表现出右心室压力升高、右心室肥厚和肺动脉重构水平升高。肺动脉血管的计算机断层扫描和血管造影显示 NFU1 大鼠严重的血管闭塞性改变。重要的是,PAH 表型的外显率在女性中比男性中更为常见,这与 PAH 患者中已建立的性别差异一致。雄性和雌性纯合子大鼠表现出线粒体复合物 II 的表达和活性降低,以及丙酮酸脱氢酶活性和脂酰基辅酶 A 结合显著降低。雄性 PAH 表型的有限发展与寡聚 NFU1 水平的保留、ISCU(铁硫组装系统的替代分支)表达增加以及复合物 IV 活性增加有关。因此,雄性具有额外的可塑性,可以克服铁硫簇缺乏。我们的工作描述了一种新型的、人源化的 NFU1 缺乏大鼠模型,该模型表现出与患者观察到的类似的线粒体功能障碍,并表现出与相同性别二态性的 PAH。